<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:wfw="http://wellformedweb.org/CommentAPI/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:sy="http://purl.org/rss/1.0/modules/syndication/" xmlns:slash="http://purl.org/rss/1.0/modules/slash/" xmlns:georss="http://www.georss.org/georss" xmlns:geo="http://www.w3.org/2003/01/geo/wgs84_pos#" > <channel> <title>Gabriela Jimenez, Author at AtG</title> <atom:link href="https://www.atgtx.com/author/gabriela/feed/" rel="self" type="application/rss+xml" /> <link>https://www.atgtx.com/author/gabriela/</link> <description>Therapeutics</description> <lastBuildDate>Thu, 04 Jul 2024 10:43:30 +0000</lastBuildDate> <language>en-US</language> <sy:updatePeriod> hourly </sy:updatePeriod> <sy:updateFrequency> 1 </sy:updateFrequency> <generator>https://wordpress.org/?v=6.5.5</generator> <site xmlns="com-wordpress:feed-additions:1">196069826</site> <item> <title>AtG Therapeutics Appoints Dr. Itziar Canamasas as New CEO to Drive Development of Cancer Metabolic Adaptation Inhibitors</title> <link>https://www.atgtx.com/news/2023/03/atg-therapeutics-appoints-dr-itziar-canamasas-as-new-ceo-to-drive-development-of-cancer-metabolic-adaptation-inhibitors/</link> <dc:creator><![CDATA[Gabriela Jimenez]]></dc:creator> <pubDate>Mon, 20 Mar 2023 07:00:00 +0000</pubDate> <category><![CDATA[News]]></category> <guid isPermaLink="false">https://www.atgtx.com/?p=17624</guid> <description><![CDATA[<p>AtG Therapeutics, a pre-clinical stage biotech focused on stopping cancer metabolic adaptation, has announced the appointment of Itziar Canamasas, PhD as its new CEO. Dr. Canamasas brings over 20 years of experience in the pharmaceutical industry, with expertise focused on global commercialisation, strategic life-cycle development, corporate strategy, and country leadership. She was most recently the […]</p> <p>The post <a href="https://www.atgtx.com/news/2023/03/atg-therapeutics-appoints-dr-itziar-canamasas-as-new-ceo-to-drive-development-of-cancer-metabolic-adaptation-inhibitors/">AtG Therapeutics Appoints Dr. Itziar Canamasas as New CEO to Drive Development of Cancer Metabolic Adaptation Inhibitors</a> appeared first on <a href="https://www.atgtx.com">AtG</a>.</p> ]]></description> <post-id xmlns="com-wordpress:feed-additions:1">17624</post-id> </item> <item> <title>La Vanguardia – Una firma surgida del ICO logra fondos para el tratamiento de cáncer avanzado</title> <link>https://www.atgtx.com/news/2022/07/la-vanguardia-una-firma-surgida-del-ico-logra-fondos-para-el-tratamiento-de-cancer-avanzado/</link> <dc:creator><![CDATA[Gabriela Jimenez]]></dc:creator> <pubDate>Sun, 24 Jul 2022 09:22:04 +0000</pubDate> <category><![CDATA[News]]></category> <guid isPermaLink="false">https://www.atgtx.com/?p=12319</guid> <description><![CDATA[<p>La empresa AtG Therapeutics, una “spin-off” surgida del IDIBELL y el Instituto Catalán de Oncología (ICO), ha cerrado una ronda de financiación con la que ha recaudado más de medio millón de euros para desarrollar alternativas terapéuticas para cánceres avanzados y un sistema de cribado para estos pacientes. Read more</p> <p>The post <a href="https://www.atgtx.com/news/2022/07/la-vanguardia-una-firma-surgida-del-ico-logra-fondos-para-el-tratamiento-de-cancer-avanzado/">La Vanguardia – Una firma surgida del ICO logra fondos para el tratamiento de cáncer avanzado</a> appeared first on <a href="https://www.atgtx.com">AtG</a>.</p> ]]></description> <post-id xmlns="com-wordpress:feed-additions:1">12319</post-id> </item> <item> <title>AtG Therapeutics completes a seed financing round raising more than half a million euros.</title> <link>https://www.atgtx.com/news/2022/07/atg-therapeutics-completes-a-seed-financing-round-raising-more-than-half-a-million-euros/</link> <dc:creator><![CDATA[Gabriela Jimenez]]></dc:creator> <pubDate>Thu, 21 Jul 2022 11:13:57 +0000</pubDate> <category><![CDATA[News]]></category> <guid isPermaLink="false">https://www.atgtx.com/?p=12275</guid> <description><![CDATA[<p>AtG Therapeutics is a recently created spin-off from IDIBELL and ICO, announces its launch with a first round of financing collecting 556,000 euros, received the support of international and national entities, including Blue Goose Capital, Women Angels for STEAM (WA4STEAM), the StapleCat/Inveniam group, and renowned international scientists. AtG Therapeutics has been founded by researchers Oriol […]</p> <p>The post <a href="https://www.atgtx.com/news/2022/07/atg-therapeutics-completes-a-seed-financing-round-raising-more-than-half-a-million-euros/">AtG Therapeutics completes a seed financing round raising more than half a million euros.</a> appeared first on <a href="https://www.atgtx.com">AtG</a>.</p> ]]></description> <post-id xmlns="com-wordpress:feed-additions:1">12275</post-id> </item> <item> <title>La Vanguardia – How can we stop cancer cells’ resistance to treatments?</title> <link>https://www.atgtx.com/news/2020/06/la-vanguardia-how-can-we-stop-cancer-cells-resistance-to-treatments/</link> <dc:creator><![CDATA[Gabriela Jimenez]]></dc:creator> <pubDate>Mon, 15 Jun 2020 14:04:14 +0000</pubDate> <category><![CDATA[News]]></category> <guid isPermaLink="false">https://www.atgtx.com/?p=3740</guid> <description><![CDATA[<p>Oriol Casanovas and Gabriela Jiménez, AtG team, answer to the “Questions for the Future” of La Vanguardia newspaper. A note on the Big Vang section, featuring research projects financed by La Caixa. Find more about the interview on the link.</p> <p>The post <a href="https://www.atgtx.com/news/2020/06/la-vanguardia-how-can-we-stop-cancer-cells-resistance-to-treatments/">La Vanguardia – How can we stop cancer cells’ resistance to treatments?</a> appeared first on <a href="https://www.atgtx.com">AtG</a>.</p> ]]></description> <post-id xmlns="com-wordpress:feed-additions:1">3740</post-id> </item> <item> <title>AtG awarded with FIPSE</title> <link>https://www.atgtx.com/news/2020/05/atg-awarded-with-fipse/</link> <dc:creator><![CDATA[Gabriela Jimenez]]></dc:creator> <pubDate>Fri, 15 May 2020 14:50:53 +0000</pubDate> <category><![CDATA[News]]></category> <guid isPermaLink="false">https://www.atgtx.com/?p=3469</guid> <description><![CDATA[<p>La Fundación para la Innovación y la Prospectiva en Salud en España (FIPSE), nos ha galardonado con una ayuda para financiar estudios de viabilidad de nuestra innovación, fuimos seleccionado como uno de los mejores proyectos de investigación del sector salud. Esta ayuda nos dotará de nuevas capacidades para desarrollar nuestros productos que generarán un alto […]</p> <p>The post <a href="https://www.atgtx.com/news/2020/05/atg-awarded-with-fipse/">AtG awarded with FIPSE</a> appeared first on <a href="https://www.atgtx.com">AtG</a>.</p> ]]></description> <post-id xmlns="com-wordpress:feed-additions:1">3469</post-id> </item> <item> <title>AtG selected to participate at CRAASH</title> <link>https://www.atgtx.com/news/2020/04/atg-selected-to-participate-at-craash/</link> <dc:creator><![CDATA[Gabriela Jimenez]]></dc:creator> <pubDate>Thu, 16 Apr 2020 17:25:14 +0000</pubDate> <category><![CDATA[News]]></category> <guid isPermaLink="false">https://www.atgtx.com/?p=3295</guid> <description><![CDATA[<p>Angiotheragnostics have been selected to participate at CRAASH. CRAASH Barcelona is a 12-week program that helps European research teams launch successful device, diagnostic and e/digital health innovations to improve health and patient care. This program is organized by Biocat in collaboration with both CIMIT and EIT Health. It is one of the flagship programs of Moebio, Biocat’s initiative for acceleration and […]</p> <p>The post <a href="https://www.atgtx.com/news/2020/04/atg-selected-to-participate-at-craash/">AtG selected to participate at CRAASH</a> appeared first on <a href="https://www.atgtx.com">AtG</a>.</p> ]]></description> <post-id xmlns="com-wordpress:feed-additions:1">3295</post-id> </item> <item> <title>AtG awarded with Caixaimpulse</title> <link>https://www.atgtx.com/news/2019/09/atg-awared-with-caixaimpulse/</link> <dc:creator><![CDATA[Gabriela Jimenez]]></dc:creator> <pubDate>Mon, 16 Sep 2019 13:57:00 +0000</pubDate> <category><![CDATA[News]]></category> <guid isPermaLink="false">https://www.atgtx.com/?p=3248</guid> <description><![CDATA[<p>Angiotheragnostics was awarded with a Caixaimpulse Grant. This is the result of hard team work. We hope that all together, with the support from Banco La Caixa, succeed in further developing a new drug to prevent cancer therapeutic resistance together with its patient selection biomarker.</p> <p>The post <a href="https://www.atgtx.com/news/2019/09/atg-awared-with-caixaimpulse/">AtG awarded with Caixaimpulse</a> appeared first on <a href="https://www.atgtx.com">AtG</a>.</p> ]]></description> <post-id xmlns="com-wordpress:feed-additions:1">3248</post-id> </item> <item> <title>AtG project at MAP- EADA entrepreneurship program</title> <link>https://www.atgtx.com/news/2019/07/atg-project-at-map-eada-entrepreneurship-program/</link> <dc:creator><![CDATA[Gabriela Jimenez]]></dc:creator> <pubDate>Wed, 17 Jul 2019 15:54:09 +0000</pubDate> <category><![CDATA[News]]></category> <guid isPermaLink="false">https://www.atgtx.com/?p=3262</guid> <description><![CDATA[<p>EADA is a Business School located in the heart of Barcelona. Its masters are ranked amongst the top in the world according to The Financial Times and it is accredited by the most reliable agencies, such as EQUIS or AACSB. EADA has developed several business collaborations with private and public agencies. One that has proven […]</p> <p>The post <a href="https://www.atgtx.com/news/2019/07/atg-project-at-map-eada-entrepreneurship-program/">AtG project at MAP- EADA entrepreneurship program</a> appeared first on <a href="https://www.atgtx.com">AtG</a>.</p> ]]></description> <post-id xmlns="com-wordpress:feed-additions:1">3262</post-id> </item> <item> <title>We are pitching at Bio€quity Europe 2019</title> <link>https://www.atgtx.com/news/2019/05/we-are-pitching-at-bioequity-europe-2019/</link> <dc:creator><![CDATA[Gabriela Jimenez]]></dc:creator> <pubDate>Mon, 20 May 2019 15:12:00 +0000</pubDate> <category><![CDATA[News]]></category> <guid isPermaLink="false">https://www.atgtx.com/?p=3258</guid> <description><![CDATA[<p>AtG has been selected to participate in Bio€quity Europe 2019. Bio€quity 2019, the most important biopharmaceutical investor conference in Europe, took place in Barcelona for the first time on May 20-21, 2019. Organized by BioCentury and EBD Group is the seminal industry event for financial dealmakers looking for investor-validated life science companies positioning themselves to attract capital, […]</p> <p>The post <a href="https://www.atgtx.com/news/2019/05/we-are-pitching-at-bioequity-europe-2019/">We are pitching at Bio€quity Europe 2019</a> appeared first on <a href="https://www.atgtx.com">AtG</a>.</p> ]]></description> <post-id xmlns="com-wordpress:feed-additions:1">3258</post-id> </item> <item> <title>We are pitching at #IMAGINE IF!</title> <link>https://www.atgtx.com/news/2019/03/we-are-pitching-at-imagine-if/</link> <dc:creator><![CDATA[Gabriela Jimenez]]></dc:creator> <pubDate>Tue, 05 Mar 2019 16:07:07 +0000</pubDate> <category><![CDATA[News]]></category> <guid isPermaLink="false">https://www.atgtx.com/?p=3254</guid> <description><![CDATA[<p>AtG has been selected to participate in IMAGINE IF! accelerator program from Innovation Forum and supported by Cambridge Squared and Johnson & Johnson Innovation. This is a global competition and accelerator for healthcare in science venture, with tailored mentoring and access to the Innovation Forum professional network from University of Cambridge and University of Oxford, […]</p> <p>The post <a href="https://www.atgtx.com/news/2019/03/we-are-pitching-at-imagine-if/">We are pitching at #IMAGINE IF!</a> appeared first on <a href="https://www.atgtx.com">AtG</a>.</p> ]]></description> <post-id xmlns="com-wordpress:feed-additions:1">3254</post-id> </item> </channel> </rss>